Press Releases

Cannasat Therapeutics to Present at BioFinance 2010 Conference

Marketwire, April 6, 2022

TORONTO, CANADA – Cannasat Therapeutics (CTH: TSX-V) announced today that Anthony Giovinazzo, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2010 Conference, being held this week in Toronto. Mr. Giovinazzo will be speaking at 9:00 a.m., on Wednesday, April 7, in Trinity Room 3 of the Toronto Marriott Eaton Centre.

BioFinance is the Canadian life science industry's leading investor conference that brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology.

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

About Cannasat Therapeutics

Cannasat is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cannasat has a lower risk Parkinson’s drug candidate, which is a reformulation of an approved drug that can address a moderate to severe patient population. Cannasat also has a proprietary formulation technology for cannabinoid drug candidates, which may be used to treat neuropathic pain associated with multiple sclerosis and cancer, as well as for nausea/vomiting and appetite stimulation. Cannasat's strategy is to grow its portfolio of drug candidates through in-licensing and acquisitions, and to advance projects to Phase 2 proof-of-concept clinical studies. Once the drug candidates are sufficiently derisked, Cannasat intends to out-license the programs to the appropriate Pharma marketing partners for a combination of upfront, milestone, and royalty payments. More information about Cannasat (CTH: TSX-V) is available at

Contact Information

Andrew M. Williams
Cannasat Therapeutics Inc.

W: 416-703-2449 (Ext. 253)
F: 416-703-8752
[email protected]


Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on